Serial circulating tumor DNA as a biomarker for monitoring and prognostication in patients with pancreatic cancer

Figure 7 Survival outcomes according to baseline circulating tumor DNA levels and circulating tumor DNA clearance after chemotherapy. A and B: Survival analysis in localized stage patients stratified by median baseline circulating tumor DNA (ctDNA) level. No significant differences were observed in either median progression-free survival (PFS) or median overall survival between the two groups; C and D: Survival outcomes in metastatic stage patients stratified by median baseline ctDNA level, patients with ctDNA levels below the median showed significantly longer median PFS and compared to those above the median; E and F: Survival analysis according to ctDNA clearance status at 8 weeks after chemotherapy initiation. While PFS showed no significant difference between groups, median overall survival was significantly longer in the clearance group compared to the non-clearance group. ctDNA: Circulating tumor DNA; VAF: Variant allele fraction.